This study focuses on four general product categories, including:

• Allergic Rhinitis Remedies;
• Sinusitis Remedies;
• Ocular Allergy Remedies; and
• Asthma Products.

In addition to the four general product categories, a section is dedicated to the potential market, which includes potential prescription to over-the-counter switches, Allegra, Claritin and Zyrtec. Product categories are described in detail and the major market factors in each category are detailed. The report describes the industry, its relationship to various healthcare delivery channels, and trends for the future. The geographic scope of the report is the United States.

The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 50 key industry officials, trade association spokespersons, consultants, health care providers, and government personnel were compiled to form the primary basis of information - specifically revenue and market share data - presented in this report.

All market data pertains to the U.S. market at the manufacturers’ level. The base year for data was 2000. Historical data are provided for 1996 through 1999, with forecast data provided for 2001 through 2006. Compound annual growth rates (CAGRs) are provided for the 1996-2000, 2000-2006, and 1996-2006 periods for each industry segment covered.

Press Release

Largest OTC Market Segment on the Verge of Big Change

New York, October 17, 2001 /PR Newswire —Big changes could be in store for the over-the-counter (OTC) allergy and asthma product market in the near future, according to a new study released today from Kalorama Information and available through MarketResearch.com. Allergy and Asthma products the largest OTC segment in the United States with sales surpassing $1.7 billion last year, could be getting some company on the already crowded drugstore shelves.

The new study, The U.S. Market for Over-the-Counter Allergy and Asthma Products, identifies at least ten likely candidates for Rx-to-OTC switches in this area in the next few years. The most important category—non-sedating antihistamines such as Claritin, Allegra, and Zyrtec—will most likely be available OTC by 2003, according to the study. These allergy medications could grab upwards of 25% of the total market almost immediately after their introduction.

Although the study found modest growth to be the norm in most of the areas covered, remedies for ocular allergies posted respectable growth (near 10%) recently, and the potential OTC candidates likely to hit the market by 2003 are forecast to post healthy growth rates (over 12%) in the subsequent years.

“Modeling OTC markets is notoriously difficult,” notes Steven Heffner, Acquisitions Editor at Kalorama. “There are many more unpredictable variables to take into account than in prescription markets: consumer behavior and brand loyalty, fierce pricing competition especially in the robust generic area, and uncertain reimbursement policies from pharmacy benefits companies. Our analysts looked at consumer and regulatory trends and compiled excellent market information from both the retail unit sales side to the manufacturers’ dollar volume to analyze this complex market.”

Related Reports:
Snapshots US Nasal Products 2009
Snapshots US Pharmaceuticals 2009
Mapping the Healthcare Landscape Bringing pharmaceuticals into focus
Snapshots Spain Pharmaceuticals 2009
Snapshots Poland Pharmaceuticals 2009
Snapshots US OTC Pharmaceuticals 2009
Snapshots Denmark OTC Pharmaceuticals 2009
Snapshots South Africa Pharmaceuticals 2009
Snapshots Hungary Pharmaceuticals 2009
Snapshots Venezuela Pharmaceuticals 2009